Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01127178 · ClinicalTrials.gov registry record · Phase 1
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Eisai.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01127178 is a Phase 1 study that was terminated before completion, run by Eisai. The registered enrollment target is 12 participants.
The verdict
NCT01127178, a Phase 1 study, was terminated before completion, sponsored by Eisai.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of poly (ADP-Ribose) polymerase inhibitor E7016 when used with temozolomide (TMZ) in patients with advanced solid tumors and gliomas.
Interventions
- DRUG E7016 + TMZ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-03-29 |
| Est. Completion | 2011-02-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01127178
The ClinicalTrials.gov registry entry for NCT01127178 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which E7016 + TMZ is the first listed.
NCT01127178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01127178 about?
NCT01127178 is a clinical study titled "Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors". The purpose of this study is to determine the maximum tolerated dose (MTD) of poly (ADP-Ribose) polymerase inhibitor E7016 when used with temozolomide (TMZ) in patients with advanced solid tumors and gliomas.
What is the current status of trial NCT01127178?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2010-03-29. Estimated completion is 2011-02-24.
What interventions are being tested in trial NCT01127178?
The interventions under investigation include: E7016 + TMZ (DRUG).
Who is sponsoring clinical trial NCT01127178?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.